The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August. FDA has approved lixisenatide, the GLP-1 receptor agonist that was the first ...

The European Commission has granted approval of lixisenatide (Lyxumia, Sanofi) for the treatment of adults with type 2 diabetes mellitus. The drug, a once-daily glucagonlike peptide 1 (GLP-1) agonist, ...

PARIS -- Sanofi announced today the presentation of full results of the Phase IIIb ELIXA study, which was designed to assess the cardiovascular (CV) safety of Lyxumia® (lixisenatide) in adults with ...

The glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Adlyxin) led to less progression of motor disability compared with placebo in early Parkinson's disease, the phase II LIXIPARK trial ...

BOSTON (updated June 9) — Lixisenatide (Lyxumia, Sanofi), an injectable glucagonlike peptide (GLP-1) agonist used for the treatment of type 2 diabetes, did not show a benefit on cardiovascular ...

Soliqua 100/33 is a brand-name prescription medication. It’s used with diet and exercise to improve blood sugar levels in adults with type 2 diabetes. Soliqua 100/33 contains two drugs: insulin ...

PARIS, March 19 (Reuters) - Drugmaker Sanofi said its lixisenatide drug for the treatment of type 2 diabetes did not increase cardiovascular risk among high risk patients in a study it conducted. The ...

Patients with early Parkinson disease who received lixisenatide had a decrease in motor disability progression, but they also experienced gastrointestinal side effects. Lixisenatide vs placebo is ...

A recent study published in the New England Journal of Medicine conducted a trial of lixisenatide to assess its effects in early Parkinson’s disease. Study: Trial of Lixisenatide in Early Parkinson’s ...